SlateStone Wealth LLC Sells 5,187 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

SlateStone Wealth LLC lessened its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 61.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,271 shares of the company’s stock after selling 5,187 shares during the period. SlateStone Wealth LLC’s holdings in TransMedics Group were worth $204,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TMDX. Principal Financial Group Inc. grew its holdings in TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares during the last quarter. State of Michigan Retirement System bought a new stake in shares of TransMedics Group during the 4th quarter valued at about $6,734,000. Public Sector Pension Investment Board bought a new stake in shares of TransMedics Group during the 3rd quarter valued at about $11,079,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of TransMedics Group by 665.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after purchasing an additional 64,872 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of TransMedics Group during the 4th quarter valued at about $3,845,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 1.2 %

Shares of TransMedics Group stock opened at $67.69 on Tuesday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $2.28 billion, a PE ratio of 72.01 and a beta of 2.12. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a 50-day simple moving average of $68.43 and a two-hundred day simple moving average of $92.75.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Robert W. Baird cut their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.